Skip to Main Content Skip to Site Map Skip to Accessibility Statement

Communications (General Information & Circulars)

MHRA DRUG SAFETY UPDATE – PSEUDOEPHEDRINE : VERY RARE RISK OF……….23rd Feb 2024

MHRA DRUG SAFETY UPDATE – CODEINE LINCTUS (CODEINE ORAL SOLUTIONS): RECLASSIFICATION TO POM 23rd Feb 2024

Revised Discounting Arrangements  23 February 2024

Valproate: important new regulatory measures for oversight of prescribing to new patients and existing female patients plus Letter  21st Feb 2024

Deletion of Fontus Health Aproderm® skin products from the Northern Ireland Drug Tariff  15th February 2024

MHRA DRUG SAFETY UPDATE- ISOTRETINOIN (ROACCUTANE▼): INTRODUCTION OF NEW SAFETY MEASURES, INCLUDING ADDITIONAL OVERSIGHT OF THE INITIATION OF TREATMENT FOR PATIENTS UNDER 18 YEARS OF AGE  13th February 2024

Prescription submission reminder 2nd February 2024

MHRA Drug Safety Update – Valproate 31st January 2024

Fluoroquinolone-antibiotics-and-Omega-3-acid-ethyl-ester-medicines 31st January 2024

Out of Pocket Expenses for Laryngectomy and Tracheostomy Products  25th January 2024

SEASONAL INFLUENZA VACCINATION OFFER TO ALL 50-64 YEAR OLDS AND ALL HSC WORKERS 17th Jan 2024

Industrial Action (18th January 2024) Communication  17th January 2024

Addition of FreeStyle Libre 3 to the NI Drug Tariff 11th January 2024

NATIONAL PATIENT SAFETY ALERT – SHORTAGE OF GLP-1 RECEPTOR AGONISTS (UPDATE) 4th January 2024

COVID-19 TREATMENTS FOR THOSE AT HIGHEST RISK: CHANGE IN REPORTING OF POSITIVE COVID-19 RAPID LFT 19th Dec 2023

MHRA Drug Safety Update – 1. Aripiprazole  2. Vitamin B12  19th Dec 2023

CONFIRMED INFLUENZA IN NORTHERN IRELAND – NICE GUIDANCE ON USE OF ANTIVIRALS NOW APPLIES  18th Dec 2023

LOOKING AFTER YOU AND/OR YOUR PHARMACY TEAM’S MENTAL HEALTH AND WELLBEING  18th December 2023

Prescription submission reminder  (pdf) 5th December 2023

Addition of Omeprazole 1mg/ml oral suspension sugar free to Part 1 of the NI DT (pdf) 3rd November 2023

Prescription submission reminder  (pdf) 2nd November 2023

An update on the BSO website (pdf)  27th October 2023

Sodium valproate: all preparations are now special containers  17th October 2023

MHRA DRUG SAFETY UPDATE – STATINS: VERY INFREQUENT REPORTS OF MYASTHENIA GRAVIS, AND FLUOROQUINOLONE ANTIBIOTICS: SUICIDAL THOUGHTS AND BEHAVIOUR  29th September 2023

THE 2023/24 SEASONAL INFLUENZA AND COVID-19 VACCINATION PROGRAMMES FOR HEALTH AND SOCIAL CARE WORKERS  11th September 2023

COVID-19 AUTUMN WINTER BOOSTER VACCINATION PROGRAMME 2023  6th September 2023

MHRA DRUG SAFETY UPDATE- VALPROATE: RE-ANALYSIS OF STUDY ON RISKS IN CHILDREN OF MEN TAKING VALPROATE  6th September 2023

MHRA Drug Safety Update – Fluoroquinolone Antibiotics 6th Sept 2023

SEASONAL INFLUENZA VACCINATION PROGRAMME 2023/24  5th September 2023

PHARMACY FOUNDATION TRAINING YEAR PLACEMENT GRANT 23/24 & Application Form  31.08.23

SHINGLES VACCINATION PROGRAMME INTRODUCTION OF SHINGRIX® VACCINE INTO THE ROUTINE PROGRAMME AND CHANGES TO ELIGIBLE COHORTS  14th August 2023

WORLD PATIENT SAFETY DAY 17 SEPTEMBER 2023

MHRA Drug Safety Update – July 2023

Apixaban and Sitagliptin prescriptions  2nd August 2023

MHRA DRUG SAFETY UPDATE AND NATIONAL PATIENT SAFETY ALERT- CALCIUM CHLORIDE, CALCIUM GLUCONATE: POTENTIAL RISK OF UNDERDOSING WITH CALCIUM GLUCONATE IN SEVERE HYPERKALAEMIA.

MHRA DRUG SAFETY UPDATE: NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS): POTENTIAL RISKS FOLLOWING PROLONGED USE AFTER 20 WEEKS OF PREGNANCY  29th June 2023

MHRA DRUG SAFETY UPDATE: ADRENALINE AUTO-INJECTORS (AAIS): NEW GUIDANCE AND RESOURCES FOR SAFE USE  29th June 2023

FEBUXOSTAT: UPDATED ADVICE FOR THE TREATMENT OF PATIENTS WITH A HISTORY OF MAJOR CARDIOVASCULAR DISEASE

GLUCOSE SOLUTIONS: RECOMMENDATIONS TO MINIMISE THE RISKS ASSOCIATED WITH THE ACCIDENTAL USE OF GLUCOSE SOLUTIONS INSTEAD OF SALINE SOLUTIONS IN ARTERIAL LINES

DIRECT-ACTING ORAL ANTICOAGULANTS (DOACS): PAEDIATRIC FORMULATIONS; REMINDER OF DOSE ADJUSTMENTS IN PATIENTS WITH RENAL IMPAIRMENT

SUMMARY – ESSURE CONTRACEPTIVE DEVICES  17th May 2023

JANUS KINASE (JAK) INHIBITORS: NEW MEASURES TO REDUCE RISKS OF MAJOR CARDIOVASCULAR EVENTS, MALIGNANCY, VENOUS THROMBOEMBOLISM, SERIOUS INFECTIONS AND INCREASED MORTALITY  02.05.23

NITROFURANTOIN: REMINDER OF THE RISKS OF PULMONARY AND HEPATIC ADVERSE DRUG REACTIONS 02.05.23

Isotretinoin (Roaccutane▼): new safety measures to be introduced in the coming months, including additional oversight on initiation of treatment for patients under 18 years  28.04.2023

CMO Letter – STRATEGY FOR MPOX (FORMERLY KNOWN AS MONKEYPOX) CONTROL plus UK Strategy 21st March 2023

CHANGES TO THE HPV VACCINATION SCHEDULE – REDUCTION TO ONE DOSE  20th March 2023

PHOLCODINE: DRUG SAFETY UPDATE- PHOLCODINE-CONTAINING COUGH AND COLD MEDICINES: WITHDRAWAL FROM UK MARKET AS A PRECAUTIONARY MEASURE  14th March 2023

Part III appliance out of pocket pilot- January 2023  14th February 2023

SUPPLY OF LICENSED AND UNLICENSED EPIDURAL BAGS – NATIONAL PATIENT SAFETY ALERT 25.01.23

CHANGES TO THE HPV VACCINATION SCHEDULE  16th January 2023

Serious Shortage Protocols: Submission Information for Contractors NI : Reminder  3rd Jan 2023

VALPROATE: DRUG SAFETY UPDATE- REMINDER OF THE CURRENT PREGNANCY PREVENTION PROGRAMME REQUIREMENTS; INFORMATION ON NEW SAFETY MEASURES  14th December 2022

GUIDANCE ON PLACE OF BIRTH: IMMEDIATE ACTION REQUIRED  22nd November 2022

Letter from Canice Ward to registered pharmacies re private prescribing  14th November 2022

Winter letter from Prof Sir Michael McBride and Attachment  14th November 2022

Grant Funding Allocation – DM+D Clinical System Amendment   9th November 2022

UPDATED COVID-19 TESTING GUIDANCE TO SUPPORT CLINICAL PATHWAYS  9th November 2022

Letter from Minister Swann  27th October 2022

PUBLIC HEALTH MESSAGE TO ALL HEALTH AND SOCIAL CARE PROVIDERS REGARDING EBOLA VIRUS OUTBREAK IN UGANDA (SUDAN EBOLAVIRUS)   updated 26th October 2022

Liothyronine prescribing: choice of formulation  20th October 2022

Promoting Safer Sleeping For Infants Guidance  13th October 2022

Revised 2022 Promoting Safe Sleeping for Infants Guidance  13th October 2022

Changes to the Distribution of Paper Copies of BNF and BNFC Letter

Changes to the Distribution of Paper BNF – Updated

Monkeypox Vaccination 27/7/22

TOPIRAMATE (TOPAMAX): Start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure

Reminder – Campaign 1 – “Know, Check, Ask”

Monkeypox Vaccination June 15 2022

MPS 2904 – Hypromellose 0.3% eye drops 10ml

Monkeypox becomes a notifiable disease in Northern Ireland 

Responsibility for prescribing between primary, secondary and tertiary care services for the supply of medicines and other pharmaceutical products letter 

Responsibility for prescribing between primary, secondary and tertiary care services for the supply of medicines and other pharmaceutical products 

Immediate actions in response to cases of Monkeypox virus in UK with no travel history 

Product Recall Information notice – Abbott recalls two infant formula powders (Update)

Contractors Providing Opioid Substitution Treatment (OST):Prescribing and Dispensing of Methadone tablets  

Reminder – Continued Use of Urgent Pandemic Packs in Nursing Homes 

Dysphagia Regional Guidance Letter 

Learning Matters Special Edition October 21

Urgent Safety Communication – Gentamicin Intrathecal 5mg/ml Solution 

Learning From Adverse Incidents – Prescribing of Strong Opioids in Syringe Drivers  

POLYETHYLENE GLYCOL (PEG) LAXATIVES AND STARCH-BASED THICKENERS: POTENTIAL INTERACTIVE EFFECT WHEN MIXED, LEADING TO AN INCREASED RISK OF ASPIRATION  

Risk to Patient Safety : Parallel Imports of Thickeners & Thickened ONS  

Revised RQIA/GAIN Hyperkalaemia Guidline  

Use of EMA authorised medicines Joint letter 

Freestyle Libre Pathway  

Patient Safety Alert – Philips Ventilator – CPAP BiPAP Devices  

Hepatitis C Becomes a Notifiable Disease in Northern Ireland  

Consultation on Duty of Candour  

Letter from Canice Ward – Sales of Ephedrine and Pseudoephedrine 

Supply Route for Insulin Safety Needles and Safety Lancets  

Medicines Optimisation Regional Efficiency (MORE) Programme Letter 

HSC Policy Statement on Implementation of MORE  

MPS 2779 – Melatonin 2mg, 3mg and 5mg capsules (Colonis Pharma Ltd) 

Combination anti-platelet therapy for patients who have a coronary stent  

Appendix A – DAPT Patient Letter  

Appendix B – DAPT Professional Staff Information Leaflet  

Potential Diversion of Oromucosal Buprenorphine (Espranor)  

National Patient Safety Alert – Corticosteroid Medication  

Oral Emergency Contraception  

Patient Safety Alert – BD I.V. and Gravity Feed Infusion Sets  

Patient Safety Alert – BD  

Patient Safety Alert – MHRA 

Controlled Drug Declaration and Self-Assessment 2021 

Changeover to Freestyle Libre 2 Sensors – Letter  / Comparrison Table  / Template / PIL

Stock Requisitions : Learning From Recent Review  

Controlled Drugs : Private Prescriptions (PCD1s) and Private Stock Requisitions (CDRF1s) – Reminder  

Learning from Serious Adverse Incident (SAI) : Action Required when a Patient Receiving Oral Substitution Treatment (OST) Misses Doses or Circumstances Change (Jan 2021)

Safety of Antiepileptic Drugs in Pregnancy – Updated Advice  

Prescribing of Vitamin D as a Preventative Measure Against COVID-19  

CPO to Healthcare Sector – Falsified Medicines Directive  

Import Declaration for Medicines and Medical Supplies  

Cannabis Based Products for Medicinal Use – UPDATE 

Phenobarbital Elixir Alcohol Level Guidance

Cannabis Based Products for Pain

Update GLP1 agnostics – Liraglutide and Semaglutide for managing overweight and obesity

HSCNI Email Step by Step User Guide

New CD Stock Requisition Forms (Schedule 2&3) 

Appendix 2 to New CD Stock Requisition Forms (Schedule 2&3) 

Also in this Section

Also in this Section